Medical Cannabis and Cannabinoids
October 3, 2023
Mpp Amie Goodin, John Crump, D. Fadool et al.
Background: Ketamine is an anesthetic that has been proven to treat chronic pain via clinical trials; yet there is a gap in knowledge regarding the impact of the concomitant use of ketamine and cannabis on pain severity. This study examined cannabis consumers who participated in a pilot Ketamine-Assisted Psychotherapy (KAP) intervention study to examine pain severity. Methods: A subanalysis of...
bioRxiv
October 2, 2023
Roxane Verdikt, Abigail A Armstrong, Jenny Cheng et al.
preprint
Cannabis, the most consumed illicit psychoactive drug in the world, is increasingly used by pregnant women. However, while cannabinoid receptors are expressed in the early embryo, the impact of phytocannabinoids exposure on early embryonic processes is lacking. Here, we leverage a stepwise in vitro differentiation system that captures early embryonic developmental cascade to investigate the...
Pharmacology, Biochemistry, and Behavior
October 2023
Antony D Abraham, Jenny L Wiley, Julie A. Marusich
The co-use of nicotine and cannabis has been steadily rising in the United States. Rodent studies suggest that delta-9-tetrahydrocannabinol (THC) could increase addictive qualities of nicotine, but whether repeated THC exposure alters self-administration of nicotine has not been tested. We hypothesized that THC would increase the reinforcing effects of nicotine and alter nicotine intake. Adult...
Pharmacology, Biochemistry, and Behavior
October 2023
Samantha L Penman, Nicole M Roeder, Erin C. Berthold et al.
Fatty acid binding protein 5 (FABP5) interacts with the endocannabinoid system in the brain via intracellular transport of anandamide, as well as Δ9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Previous work has established the behavioral effects of genetic deletion of FABP5, but not in the presence of THC. The present study sought to further elucidate the role of...
Revista Portuguesa de Psiquiatria e Saúde Mental
September 30, 2023
Rodrigo Saraiva, Ricardo Coentre
N/A
Neuroradiology
September 22, 2023
M. Fenzl, Martin Backens, Silviu Bodea et al.
4 citations
PURPOSE: This prospective cross-sectional study investigated the influence of regular cannabis use on brain metabolism in young cannabis users by using combined proton and phosphorus magnetic resonance spectroscopy. METHODS: The study was performed in 45 young cannabis users aged 18-30, who had been using cannabis on a regular basis over a period of at least 2 years and in 47 age-matched...
Brazilian Journal of Health Review
September 21, 2023
Ingra Dalcin Pereira, João Ricardo Girotto
1 citation
A esquizofrenia representa um transtorno incapacitante com relação genética e com fatores ambientais. Entre os fatores ambientais está o consumo de substâncias psicoativas como a cannabis. O uso dessa substância tem sido frequentemente associado à geração de episódios de psicose, sintomas psiquiátricos, sendo aventada uma importante relação com a esquizofrenia. OBJETIVO: Avaliar como se dá a...
International Journal of Environmental Research and Public Health
September 18, 2023
Samantha Hurn
This report documents the case of a patient (the author) participating in a clinical trial of medical cannabis (Cannabis sativa L.)-the Sapphire Access Scheme, run by the Sapphire Medical Clinic as part of the UK Medical Cannabis Registry-to explore the impacts of cannabis-based medicinal products (CBMPs) on anxiety. For most of my life, I have experienced often very serious bouts of poor...
Trials
September 9, 2023
Zach Walsh, Ian Mitchell, Kim Crosby et al.
The last few decades have seen increasing interest in the use of cannabis for post-traumatic stress disorder (PTSD). Recent attempts to evaluate the clinical efficacy of cannabis for PTSD were inconclusive and generalizability was limited by undesirable features of the study drug. The present clinical trial evaluated the effects of a commercially available chemovar that was delivered by...
EClinicalMedicine
September 8, 2023
Mathilde Argote, Guillaume Sescousse, Jérôme Brunelin et al.
31 citations
Background: The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important...
Current Addiction Reports
September 8, 2023
Anna Ross, Jake Hawthorn
Abstract Purpose of Review The use of certain illicit substances as a form of therapy, and particularly as an adjunct to psychotherapy, has gained increasing media and academic attention over the last decade, culminating in what has been coined “the psychedelic renaissance.” This section in Current Addiction Reports has been developed in order to highlight the new and emerging research around...
Cannabis and Cannabinoid Research
September 2023
Catherine F Moore, Julie A. Marusich, Mehdi Haghdoost et al.
Introduction: Cannabis contains a multitude of phytocannabinoids and terpenes in addition to its main psychoactive constituent, delta-9-tetrahydrocannabinol (D9-THC). It is believed that the combination of minor cannabinoids and terpenes with D9-THC may impact the subjective and physiological effects of D9-THC. In this study, select minor cannabinoids (cannabigerol [CBG], cannabidivarin [CBDV],...
Addictive Behaviors
September 2023
Kat Petrilli, Lindsey A. Hines, Sally Adams et al.
Cannabis potency (concentration of Δ-9-Tetrahydrocannabinol) has been associated with risks of adverse mental health outcomes and addiction but no studies have triangulated evidence from self-report and objective measures of cannabis potency. We hypothesised that users of high potency cannabis would have higher levels of (a) anxiety, (b) depression and (c) psychosis-like symptoms (d) cannabis...
NEJM evidence
September 2023
Philip E Mosley, Lachlan Webb, Anastasia Suraev et al.
BACKGROUND: Tourette syndrome is characterized by chronic motor and vocal tics. There is preliminary evidence of benefit from cannabis products containing Δ9-tetrahydrocannabinol (THC) and that coadministration of cannabidiol (CBD) improves the side-effect profile and safety. METHODS: In this double-blind, crossover trial, participants with severe Tourette syndrome were randomly assigned to a...
Indian Journal of Psychiatry
September 1, 2023
Soumya Jha, Rupa Jha, Wenona Fernandes et al.
1 citation
Context: Cannabis use has been the most commonly used illicit psychoactive substance in India. Increasing use of cannabis has been associated with an increased risk of co-morbid psychotic spectrum disorders with worse outcomes. This risk increases with increased use in a dose-dependent manner. A very complex association exists between cannabis use and mental illness hence it is essential to...
International Journal of Mental Health and Addiction
August 29, 2023
Andrea Escelsior, Alice Trabucco, M. Radicati et al.
Time perception received growing interest in psychiatry for its psychopathological implications. Cannabis use can cause a subjective experience of temporal perception alteration and increases the risk of emergence of mental illnesses such as psychotic and mood disorders. In this framework, we systematically reviewed the findings regarding the clinical, cognitive, and neurobiological correlates...
International Journal of Molecular Sciences
August 22, 2023
Alistair V W Nunn, Geoffrey W Guy, Jimmy D Bell
Before the late 1980s, ideas around how the lipophilic phytocannabinoids might be working involved membranes and bioenergetics as these disciplines were "in vogue". However, as interest in genetics and pharmacology grew, interest in mitochondria (and membranes) waned. The discovery of the cognate receptor for tetrahydrocannabinol (THC) led to the classification of the endocannabinoid system...
L'Encephale
August 19, 2023
Tangui Barré, Faredj Cherikh, Patrizia Carrieri et al.
Cannabis use is being increasingly liberalized worldwide, and an increasing prevalence of cannabis-use disorder (CUD) is observed. The few current therapeutic options for CUD are only modestly effective. Mindfulness-based interventions offer promising prospects for the management of substance-use disorders. However, despite proliferating literature on mindfulness and substance use, few studies...
Drugs, Habits and Social Policy
August 18, 2023
Aleksi Hupli, Ali Ünlü, Jussi Jylkkä et al.
9 citations
Purpose Cannabis use continues to increase worldwide, and a number of nation states are changing their cannabis policies. Policy changes require research into key populations, namely, people who use cannabis. This study aims to examine sociodemographic differences of young Finns who reported using cannabis mainly for self-medication versus mainly recreationally, as well as their reported...
Life Sciences
August 15, 2023
Lily Freeman-Striegel, John Hamilton, Renuka Kannappan et al.
Acute and chronic Δ9-THC exposure paradigms affect the body differently. More must be known about the impact of chronic Δ9-THC on cannabinoid-1 (CB1R) and mu-opioid (MOR) receptor levels in the brain. The present study examined chronic Δ9-THC's effects on CB1R and MOR levels and locomotor activity. Adolescent Sprague-Dawley rats were given daily intraperitoneal injections of Δ9-THC [0.75mg/kg...